Acadian Asset Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Acadian Asset Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.17M	Buy	163,545 +143,436	+713%	+$1.4M	﹤0.01%	1059
2026 Q1	$186K	Sell	20,109 -10,022	-33%	-$87.2K	﹤0.01%	1610
2025 Q4	$225K	Sell	30,131 -24,970	-45%	-$253K	﹤0.01%	1497
2025 Q3	$478K	Sell	55,101 -275,490	-83%	-$1.65M	﹤0.01%	1235
2025 Q2	$1.23M	Sell	330,591 -70,015	-17%	-$246K	﹤0.01%	942
2025 Q1	$1.29M	Buy	400,606 +367,317	+1,103%	+$1.73M	﹤0.01%	869
2024 Q4	$185K	Buy	+33,289	New	+$261K	﹤0.01%	1269
2022 Q4	–	Sell	-56,592	Closed	-$454K	–	1825
2022 Q3	$454K	Sell	56,592 -38,367	-40%	-$347K	﹤0.01%	1015
2022 Q2	$663K	Buy	+94,959	New	+$923K	﹤0.01%	904

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Acadian Asset Management's FDMT Position: Q2 2026 in Review

Acadian Asset Management increased its 4D Molecular Therapeutics (FDMT) stake by 713% in Q2 2026, buying an estimated $1.4M and bringing the position to 163,545 shares worth $2.17M. The position accounts for ﹤0.01% of the portfolio, ranked #1059.

Acadian Asset Management first reported a position in FDMT in Q2 2022 and has held it in 9 quarters since. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Acadian Asset Management held 163,545 shares of 4D Molecular Therapeutics worth $2.17M as of Q2 2026.
Acadian Asset Management bought 143,436 4D Molecular Therapeutics shares in Q2 2026, an estimated $1.4M.
4D Molecular Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1059 holding.
Acadian Asset Management first reported a position in 4D Molecular Therapeutics in Q2 2022 and has held it in 9 quarters since.
158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.